Table 2. Characteristics of included studies.
| Studies | DM*,% | HTN†,% | Currentsmoker,% | PreviousMI‡, % | PreviousPCI§, % | PreviousCABG||, % | Stent length(per patient),mm | Stent length(per lesion),mm | Stentnumbers(per patient),n | Stentnumbers(per lesion),n |
| COMPARE II16 | 21.7 | 55.3 | 29.7 | 19.8 | 17.5 | 5.8 | NA | NA | NA | 1.4 |
| SORT OUT V17 | 15.2 | 56.4 | 33.3 | 17.5 | 16.9 | 7.0 | 22.5 | 15 | NA | NA |
| NOBORI 1 (Phase1+2)25–26,31 | 18.5 | 63.3 | 21.0 | 22.6 | 20.6 | 3.7 | NA | NA | NA | NA |
| LEADERS18,27 | 24.3 | 73.1 | 24.6 | 32.4 | 36.6 | 11.5 | NA | 23.7 | NA | 1.3 |
| NOBORI JAPAN28 | 39.0 | 79.8 | 22.7 | 20.9 | 35.1 | 1.5 | NA | NA | NA | NA |
| Separham, et al30 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| NEXT29 | 46 | 81.5 | 18.5 | 28.0 | 50.5 | 5.1 | 32.9 | 27.1 | 1.6 | 1.3 |
*
DM: diabetes mellitus;
†
HTN: hypertension;
‡
MI: myocardial infarction;
§
PCI: percutaneous coronary intervention;
||
CABG: coronary artery bypass.